Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy
- 9 April 2020
- journal article
- research article
- Published by IOP Publishing in Nanotechnology
- Vol. 31 (30), 305702
- https://doi.org/10.1088/1361-6528/ab884d
Abstract
Melanoma (MM) is a highly aggressive skin cancer with limited treatment options. Although chemotherapy has been using for advanced melanoma treatment, the lack of targetability, the poor biocompatibility and the severe side effects still hamper the wide applications of chemotherapy agents in MM management. Herein, a biocompatible and biodegradable polymeric hyaluronic acid nanoparticle (HANP) encapsulated with Paclitaxel (PTX) was developed for MM targeted therapy. Our results showed that PTX at 37 ± 2.1% (w/w) was able to be loaded into HANP with over five days of stability under physiological conditions. In vitro, HANP/PTX presented hyaluronidase-dependent drug release. Compared to free PTX, HANP/PTX demonstrated a 6–75 times higher growth inhibition in five different cancer cells, while only presenting minimum toxicity to normal cells. After intravenous administration at a 10 mg/kg equivalent dose of PTX, HANP/PTX significantly ablated MM tumor growth in a mouse model. As confirmed by 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging, the tumors started to respond to the HANP/PTX as early as seven days after the initial treatment, which will significantly benefit for personalized treatment. In conclusion, the HANP/PTX nanocomplex demonstrated great promise as a translational nanomedicine for cancer chemotherapy.Keywords
Funding Information
- Norman Bethune Program of Jilin University (2015219)
- National Science Foundation of China (81771869, 81871384)
This publication has 52 references indexed in Scilit:
- Designing Paclitaxel Drug Delivery Systems Aimed at Improved Patient Outcomes: Current Status and ChallengesISRN Pharmacology, 2012
- Hyaluronic Acid Receptor CD44 Deficiency Is Associated with Decreased Cryptococcus neoformans Brain InfectionOnline Journal of Public Health Informatics, 2012
- Smart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer TherapyACS Nano, 2011
- Expression of lymphatic endothelium-specific hyaluronan receptor LYVE-1 in the developing mouse kidneyCell and tissue research, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(ε-caprolactone) nanoparticles: Preparation and antitumor activity in vivoJournal of Controlled Release, 2010
- Self-assembled hyaluronic acid nanoparticles for active tumor targetingBiomaterials, 2010
- Targeting of albumin-embedded paclitaxel nanoparticles to tumorsNanomedicine: Nanotechnology, Biology and Medicine, 2009
- Signal Transduction of Hyaluronic Acid−Peptide Conjugate for Formyl Peptide Receptor Like 1 ReceptorBioconjugate Chemistry, 2008
- Specialization of tumour vasculatureNature Reviews Cancer, 2002